SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is experiencing heightened investor activity driven by a strategic partnership with Honda and growing anticipation surrounding the upcoming World Ducati Week, where the community expects potential updates on solid-state battery testing. While some investors remain skeptical about the timeline for commercial scale and the impact of insider stock sales, bullish sentiment is fueled by the company's progress in anode-free technology and its expansion into high-growth sectors like AI data center power.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing significant selling pressure as investors await the upcoming AGM for concrete execution updates and clarity on production scaling. While the community remains polarized by the stock's recent volatility, many continue to debate the company's long-term potential as a key player in photonics and AI infrastructure despite the current lack of widespread institutional revenue confirmation.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing intense volatility and downward pressure as investors rotate out of semiconductor and tech holdings due to escalating geopolitical tensions in the Middle East and concerns over stretched AI valuations. The community is actively debating whether current price levels represent a high-conviction discount buying opportunity or a deeper correction for this leveraged ETF.

Bank of Montreal engages in the provision of banking and financial services to individuals and institutions. It operates through the following segments: Canadian Personal and Commercial Banking (Canadian P&C), United States Personal and Commercial Banking (U.S. P&C), BMO Wealth Management, BMO Capital Markets, and Corporate Services. The company was founded by Robert Armour, John C. Bush, Austin Cuvillier, George Garden, Horatio Gates, James Leslie, George Moffatt, John Richardson and Thomas A. Turner on June 23, 1817 and is headquartered in Montreal, Canada.

Bank of Montreal - MicroSectors Gold Miners 3X Leveraged ETN

GDXU is currently experiencing extreme volatility as investors debate whether the recent sharp pullback is a temporary liquidity shakeout or a broader trend reversal for gold miners. The community is actively tracking technical support levels and broader macroeconomic factors like treasury yields and interest rate expectations to determine if this dip offers an accumulation opportunity or a signal to exit.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is currently trending as community discourse intensifies over reports regarding Donald Trump's significant financial gains from crypto and stock trading during his presidency. Supporters and critics remain deeply divided, with discussions centering on political loyalty, accusations of market manipulation, and the broader implications of his administration's policies on national and economic affairs.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is experiencing a significant surge, fueled by momentum from successful clinical data for its subcutaneous Briumvi treatment and growing speculation regarding a potential buyout as institutional interest climbs. The community is actively discussing the stock's transition toward record levels, often highlighting the significant short position and the potential for a squeeze as investor confidence in the company's long-term revenue growth intensifies.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The GDX ETF is facing intense scrutiny as investors debate whether central bank gold accumulation and structural supply deficits will catalyze a long-term rally or if inflationary pressures and interest rate volatility will force a deeper correction. Market participants are currently focused on the disconnect between soaring physical demand and the recent price pullback, with many closely tracking interest rate expectations and the Federal Reserve's next policy moves for signs of a turnaround.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as retail investors react to increased volatility and speculation surrounding the companys manufacturing scale, potential smart eyewear partnerships, and strategic pivot toward defense and drone applications. While some community members remain skeptical and maintain short positions based on past delays, bulls are actively debating the long-term potential of the firm's silicon-anode battery technology and monitoring technical indicators for signs of a sustained breakout.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending as investors weigh strong pivotal trial results for its Duchenne muscular dystrophy gene therapy against regulatory uncertainty and recent financial challenges. The community is actively discussing the company's long-term potential, the impact of recent clinical holds, and the market implications of its current cash runway.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing significant upward momentum as investors react to a positive delivery beat and raised annual production guidance, fueling active community debate regarding the company's ability to successfully scale its R2 platform. Market participants are closely watching the stock's ability to maintain technical support levels amidst heavy institutional volume and ongoing discussions about Rivian's long-term competitive positioning against other major EV players.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales 

Equity

Saudi Arabia is key to the bull case after ImmunityBio launched Anktiva there for certain patients with bladder and lung cancer.

ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?

ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology

XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.

IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes 

The semi-annual reconstitution of the index, based on market capitalizations as of April 30, 2026, will take effect after the U.S. market close on Friday, June 26. 

Nasdaq, S&P 500 Futures Rebound As Micron Rally Lifts Chip Stocks: Why SPCX, QCOM, TSM, BABA, PLTR, CBRS, WEN, IBRX Are In Focus 

Retail sentiment remained cautious, with Stocktwits data showing SPY sentiment stuck in bearish territory while QQQ sentiment improved to bullish.


IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying 

IBRX is already part of the Russell 2000, Russell 2500, and Russell 3000, with its current market cap around $7.67 billion.

Nasdaq, S&P 500 Futures Gain Ahead Of Kevin Warsh’s First Fed Meeting: Why SPCX, ASTS, INTC, MU, SOFI, SMCI Are In Focus

Stocktwits data showed retail sentiment has improved to ‘bullish’ on SPY and ‘neutral’ on QQQ from ‘bearish’ earlier in the week.

The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers

Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized...

IBRX and the BCG Shortage: Deals That Could Expand Demand

ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are monitoring massive short interest and heavy short volume, anticipating a violent price surge as hedge funds are forced to cover positions.

Buzz is building around ongoing international developments, including Saudi partnership rumors and potential worldwide product launches.

Traders are intensely scouting for the next major press release or official corporate announcement to act as a definitive momentum spark.

The community is aggressively discussing perceived market manipulation by institutional entities and friction with regulators.

Long-term believers are actively using dips in the current trading range to add to their holdings, citing future growth and platform scalability.

Current Price	$9.44
Prev Close	$9.20
Open	$9.23
Dividend Yield	0.00%
50-Day Moving Average	$7.68
Beta	1.82
Avg. Volume	13.3M
PE Ratio	-11.05

52-Week High	$12.43
52-Week Low	$1.95
Market Capitalization	$9.64B
EPS (Annual)	-$0.382
Price to Book	-11.36
Revenue Per Employee	$163,947.90

Feed

News

Sentiment

Fundamentals

Info

IBRXImmunityBio Inc

Latest IBRX News